Rigel PharmaceuticalsFRA:RI2 +4.41%78 Median PS Value is €53.43 as of Jun. 25, 2026, which is 100% below its 10-year median of 0.20. GuruFocus rates FRA:RI2 with a GF Score™ of 78/100 and a GF Value™ of €23.86. The stock has 8 warning signs investors should review. Among 277 Biotechnology companies, Rigel Pharmaceuticals ranks better than 54.51% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Rigel Pharmaceuticals's Median PS Value or its related term are showing as below:
FRA:RI2'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07 Med: 0.2 Max: 0.64
Current: 0.58
During the past 13 years, the highest Price to Median PS Value of Rigel Pharmaceuticals was 0.64. The lowest was 0.07. And the median was 0.20.
FRA:RI2's Price-to-Median-PS-Value is ranked better than 54.51% of 277
companies
in the Biotechnology industry
Industry Median: 0.63
vs FRA:RI2: 0.58
Rigel Pharmaceuticals (FRA:RI2) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Rigel Pharmaceuticals's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
30.77
/
53.43
=
0.58
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals Median PS Value Related Terms
Rigel Pharmaceuticals Median PS Value Historical Data
* Premium members only.
The historical data trend for Rigel Pharmaceuticals's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:RI2 vs CBIO, TRAX, GYRE: Median PS Value Comparison
For the Biotechnology subindustry, Rigel Pharmaceuticals's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rigel Pharmaceuticals Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Rigel Pharmaceuticals's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 3.9651.
Rigel Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €13.475.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals (FRA:RI2) has a Median PS Value of €53.43 as of Jun. 25, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Rigel Pharmaceuticals and its competitors. This is 26615% above median its historical median of 0.20. Over the past decade, Rigel Pharmaceuticals' Median PS Value has ranged from 0.07 to 0.64. According to the industry distribution chart, Rigel Pharmaceuticals ranks #126 out of 277 companies in the Biotechnology industry, placing it in the top 45.5%.
Is Rigel Pharmaceuticals' Median PS Value too high?
Rigel Pharmaceuticals' current Median PS Value of €53.43 is 26615% above median its 10-year median of 0.20. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 0.64. Based on the distribution chart, Rigel Pharmaceuticals ranks #126 out of 277 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Rigel Pharmaceuticals has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Rigel Pharmaceuticals' Median PS Value compare to CBIO and TRAX?
According to the Biotechnology industry distribution chart, Rigel Pharmaceuticals ranks #126 out of 277 companies for Median PS Value. This puts Rigel Pharmaceuticals in the upper half of its industry. The industry median Median PS Value is 0.63. Historically, Rigel Pharmaceuticals' own Median PS Value has ranged from 0.07 to 0.64 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.63, based on 277 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Rigel Pharmaceuticals and its competitors. For the Biotechnology industry, the median Median PS Value is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rigel Pharmaceuticals's current Median PS Value is €53.43, which is 26615% above median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rigel Pharmaceuticals stock overvalued right now?
Rigel Pharmaceuticals (FRA:RI2) has a current Median PS Value of €53.43. The stock's GF Value™ is €23.86, compared to a current price of €30.77 — trading 29% above its estimated fair value. The current Median PS Value is €53.43, which is 26615% above median its 10-year median of 0.20. Rigel Pharmaceuticals' overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Rigel Pharmaceuticals (FRA:RI2), the current Median PS Value is €53.43 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rigel Pharmaceuticals (FRA:RI2) Overvalued in 2026?
Based on GuruFocus' analysis, Rigel Pharmaceuticals stock appears to be overvalued.
The current stock price of €30.77 is trading 29% above its estimated GF Value™ of €23.86.
Key valuation signals for FRA:RI2:
Median PS Value: €53.43 (26615% above median its 10-year median of 0.20)
GF Value™: €23.86 vs. price of €30.77 (29% above fair value)
No single metric tells the full story. See the FRA:RI2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
78GF Score
Get the complete analysis for FRA:RI2
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:RI2 has been successfully added to your 
